Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice (Q39904702)

15 September 2017

Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice (English)

1 reference

15 September 2017

hepatocellular carcinoma

1 reference

1 reference

8

Edward K Geissler

1 reference

15 September 2017

Sven A Lang

1

1 reference

15 September 2017

Christian Moser

2

1 reference

15 September 2017

Stefan Fichnter-Feigl

3

1 reference

15 September 2017

Philipp Schachtschneider

4

1 reference

15 September 2017

Claus Hellerbrand

5

1 reference

15 September 2017

Volker Schmitz

6

1 reference

15 September 2017

Hans J Schlitt

7

1 reference

15 September 2017

Oliver Stoeltzing

9

1 reference

15 September 2017

language of work or name

English

0 references

publication date

1 February 2009

1 reference

15 September 2017

1 reference

15 September 2017

49

1 reference

15 September 2017

523-532

1 reference

15 September 2017

2

1 reference

Focus on hepatocellular carcinoma.

15 September 2017

1 reference

Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.

21 January 2018

1 reference

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer

21 January 2018

1 reference

Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model

21 January 2018

1 reference

mTOR and P70 S6 kinase expression in primary liver neoplasms

21 January 2018

1 reference

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins

21 January 2018

1 reference

Heat shock protein 90 as a molecular target for cancer therapeutics

21 January 2018

1 reference

A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues

21 January 2018

1 reference

Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer

21 January 2018

1 reference

Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces or

21 January 2018

1 reference

Targeting multiple signal transduction pathways through inhibition of Hsp90.

21 January 2018

1 reference

Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma

21 January 2018

1 reference

Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo

21 January 2018

1 reference

Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer

21 January 2018

1 reference

Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides

21 January 2018

1 reference

Establishment of an orthotopic tumour model for hepatocellular carcinoma and non-invasive in vivo tumour imaging by high resolution ultrasound in mice

21 January 2018

1 reference

Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma

21 January 2018

1 reference

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

21 January 2018

1 reference

Akt shows variable sensitivity to an Hsp90 inhibitor depending on cell context.

21 January 2018

1 reference

The IGF axis and hepatocarcinogenesis

21 January 2018

1 reference

Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis

21 January 2018

1 reference

The potential role of hypoxia inducible factor 1alpha in tumor progression after hypoxia and chemotherapy in hepatocellular carcinoma

21 January 2018

1 reference

Pericytes and vascular stability

21 January 2018

1 reference

Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells

21 January 2018

1 reference

Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected

21 January 2018

1 reference

NF-kappaB and cancer-identifying targets and mechanisms

21 January 2018

1 reference

Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis

21 January 2018

1 reference

The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells.

21 January 2018

1 reference

Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma

21 January 2018

1 reference

Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice

21 January 2018

1 reference

Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/HEP.22685

1 reference

15 September 2017

1 reference